Aaron and Scott discuss the urgent need for diabetes innovation in underserved countries like Malawi and the potential impact of generic insulins on major manufacturers like Novo and Lily. The conversation highlights the hope for glucose responsive insulin to revolutionize diabetes treatment worldwide.
